In a middle‑aged woman with a history of left‑breast cancer treated by mastectomy five years ago (currently on tamoxifen) who now has chronic right‑hip pain and lumbar L3‑L4/L4‑L5 stenosis, does a lumbar spine and hip MRI reliably exclude bone metastases, or should a whole‑body bone scan or FDG‑PET/CT be performed, and is a DEXA scan appropriate for assessing bone health?

MRI Alone Is Insufficient to Exclude Bone Metastases in This High-Risk Patient

In a breast cancer survivor with chronic hip and spine pain, a lumbar spine and hip MRI—while excellent for evaluating spinal stenosis—cannot reliably exclude bone metastases elsewhere in the skeleton, and you should proceed with whole-body metabolic imaging (bone scan or FDG-PET/CT) to assess for occult metastatic disease. The DEXA scan is appropriate for assessing treatment-related bone loss from tamoxifen but serves an entirely different purpose and will not detect malignancy.

Why MRI Has Critical Limitations Here

MRI only images what you scan. While MRI is more sensitive than bone scintigraphy for detecting spinal metastases in the specific anatomic region imaged 1, it provides no information about the rest of the skeleton. Breast cancer metastasizes to bone in 65-75% of metastatic cases 2, and these lesions are typically multifocal, affecting ribs, pelvis, proximal femurs, and other sites beyond the lumbar spine and single hip 1, 3.

The key problem: Her lumbar MRI may show degenerative stenosis at L3-L5, but metastatic disease could be present in thoracic vertebrae, ribs, contralateral hip, or pelvis—all invisible on a limited regional study. MRI directly visualizes metastatic tumor based on signal intensity differences from normal bone marrow 1, but only where you look.

The Appropriate Imaging Strategy

For Metastatic Screening (Your Primary Concern)

Order FDG-PET/CT as the single most comprehensive test 1. The 2020 ESMO guidelines emphasize that PET imaging has "significant advantages over bone scintigraphy for evaluation of skeletal metastatic disease, including superior diagnostic accuracy, higher spatial resolution and shorter imaging times" 1.

FDG-PET/CT provides:

• Whole-body skeletal assessment in one study
• Detection of both lytic and sclerotic lesions (though lytic lesions show greater FDG uptake) 1
• Simultaneous evaluation for visceral metastases
• Ability to differentiate metabolically active disease from inactive sclerotic changes 1

Alternative: Tc-99m bone scan if PET/CT is unavailable or not covered. Bone scintigraphy remains more sensitive than plain radiographs and provides whole-body skeletal evaluation 1. However, it has lower specificity and can be confounded by degenerative changes—a significant issue in your patient with known lumbar stenosis 1, 4.

Critical Caveat About Breast Cancer Biology

Slowly proliferating breast cancer metastases can be FDG-negative 1. If PET/CT is equivocal or negative but clinical suspicion remains high (persistent unexplained pain, rising tumor markers if checked), consider adding 18F-sodium fluoride PET, which is "superior to 99Tc bone scintigraphy and comparable to diffusion-weighted MRI for diagnosis" 1. However, this agent is expensive and not widely available 1.

When Biopsy Becomes Essential

If imaging shows few lesions or equivocal findings, obtain histological confirmation 1. The 2020 ESMO guidelines state: "In bone-only disease, especially when there are few lesions or imaging tests are equivocal, histological confirmation of metastatic disease is strongly recommended" 1. CT-guided biopsy allows both diagnosis and reassessment of biomarkers (ER/PR/HER2 status) that may have changed from the primary tumor 1.

The Role of DEXA Scanning (Separate Issue)

DEXA is appropriate but addresses a different problem entirely. Tamoxifen causes bone loss in premenopausal women (mean 1.44% annual lumbar spine BMD loss) 5 but has a protective effect in postmenopausal women 5. Your patient, five years post-mastectomy and on tamoxifen, needs baseline BMD assessment per ESMO guidelines 6, 7.

DEXA will:

• Quantify treatment-related osteoporosis risk
• Guide decisions about bisphosphonates or denosumab for bone health 6
• Establish baseline for monitoring

DEXA will NOT:

• Detect metastatic disease (it measures density, not tumor) 7
• Differentiate benign from malignant bone changes
• Provide diagnostic information about her pain

Common Pitfall to Avoid

Do not assume that a "normal" regional MRI excludes metastatic disease. The 2020 ESMO guidelines explicitly note that confusion with benign pathology (degenerative disease, osteoporosis) is "particularly problematic in elderly patients" 1. Your patient's stenosis is real, but it doesn't explain away the need to screen for metastases in a breast cancer survivor with new or worsening skeletal symptoms.

The imaging sequence should be:

1. FDG-PET/CT (or bone scan if PET unavailable) for whole-body metastatic screening
2. DEXA scan for bone health assessment (separate indication)
3. Biopsy if imaging shows oligometastatic or equivocal disease
4. Continue using the existing lumbar/hip MRI for surgical planning if stenosis requires decompression

This approach addresses both the cancer surveillance question (whole-body metabolic imaging) and the bone health question (DEXA) without conflating the two distinct clinical issues.